Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
Neuro Central,
− Approval based on Phase 1/2 trial results, which demonstrated clinically meaningful responses with a median duration of…